Current Report Filing (8-k)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): June 5, 2017

 

 

CEL-SCI CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

Colorado	001-11889	84-0916344
(State or other jurisdiction	(Commission File No.)	(IRS Employer
of incorporation)		Identification No.)

 

 

8229 Boone Boulevard, Suite 802

Vienna, Virginia 22182 

 (Address of principal executive offices, including Zip Code)

 

 

Registrant’s telephone number, including area code: [phone]

 

  N/A

(Former name or former address if changed since last report)

 

 

 

 

 

Item 8.01    Other Events

 

On June 5, 2017 the Company issued a press release, filed as Exhibit 99, announcing that it has responded to the U.S. Food and Drug Administration’s (FDA) most recent communication.

 

Item 9.01    Exhibits

 

Exhibit
Number	Description of Document
99	June 5, 2017 Press Release.

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Date: June 5, 2017	CEL-SCI CORPORATION
	By:	/s/  Patricia B. Prichep
		Patricia B. Prichep
		Senior Vice President of Operations